Skip to main content

Advertisement

SpringerLink
Log in

Systemic chemotherapy as a main strategy for liver metastases from gastric cancer

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Background

Liver metastasis is associated with poor prognosis in gastric cancer. Surgical resection and systemic chemotherapy have been reported to be effective in gastric cancer with liver metastasis (GCLM). However, the best strategy for GCLM has not been established.

Methods

From May 2009 to July 2014, a consecutive series of GCLM patients in Zhongshan Hospital of Fudan University were studied. Treatment strategies were evaluated with regard to different extents of metastases.

Results

A total of 163 patients were included. The overall survival was 10.1 months. Active treatment significantly prolongs the survival of GCLM patients. The overall survival time for patients with liver-limited metastases and extra-hepatic liver metastases was 11.6 mo and 8.7 mo, respectively (P = 0.012). The median survival time for liver-limited disease of H1, H2 and H3 was 14.2, 15.8, and 8.5 months, respectively (H3 vs H2, P = 0.001; H3 vs H1, P = 0.000; H1 vs H2, P = 0.900). Systemic chemotherapy was chosen as the main strategy for the ‘extensive’ patients with extra-hepatic metastases and H3 type liver-limited metastases. Patients’ survival was benefited by multi-line chemotherapy. No differences were shown between systemic chemotherapy and curative resection or palliative resection in H1 and H2 liver-limited metastases (16.0 mo vs 12.0 mo, P = 0.711; 16.0 vs 18.8 months, P = 0.654).

Conclusion

Systemic chemotherapy was the main treatment for gastric cancer patients with liver metastases. Curative resection could be considered for highly selected patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  PubMed  Google Scholar 

  2. Okano K, Maeba T, Ishimura K, Karasawa Y, Goda F, Wakabayashi H, et al. Hepatic resection for metastatic tumors from gastric cancer. Ann Surg. 2002;235(1):86–91.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Sakamoto Y, Ohyama S, Yamamoto J, Yamada K, Seki M, Ohta K, et al. Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients. Surgery. 2003;133(5):507–11.

    Article  PubMed  Google Scholar 

  4. Koga R, Yamamoto J, Ohyama S, Saiura A, Seki M, Seto Y, et al. Liver resection for metastatic gastric cancer: experience with 42 patients including eight long-term survivors. Jpn J Clin Oncol. 2007;37(11):836–42.

    Article  PubMed  Google Scholar 

  5. Cheon SH, Rha SY, Jeung HC, Im CK, Kim SH, Kim HR, et al. Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol. 2008;19(6):1146–53.

    Article  CAS  PubMed  Google Scholar 

  6. Qiu JL, Deng MG, Li W, Zou RH, Li BK, Zheng Y, et al. Hepatic resection for synchronous hepatic metastasis from gastric cancer. Eur J Surg Oncol. 2013;39(7):694–700.

    Article  PubMed  Google Scholar 

  7. Sakamoto Y, Sano T, Shimada K, Esaki M, Saka M, Fukagawa T, et al. Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer. J Surg Oncol. 2007;95(7):534–9.

    Article  PubMed  Google Scholar 

  8. Marrelli D, Roviello F, De Stefano A, Fotia G, Giliberto C, Garosi L, et al. Risk factors for liver metastases after curative surgical procedures for gastric cancer: a prospective study of 208 patients treated with surgical resection. J Am Coll Surg. 2004;198(1):51–8.

    Article  PubMed  Google Scholar 

  9. D’Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004;240(5):808–16.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Jerraya H, Saidani A, Khalfallah M, Bouasker I, Nouira R, Dziri C. Management of liver metastases from gastric carcinoma: where is the evidence? Tunis Med. 2013;91(1):1–5.

    PubMed  Google Scholar 

  11. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215–21.

    Article  CAS  PubMed  Google Scholar 

  12. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10(11):1063–9.

    Article  CAS  PubMed  Google Scholar 

  13. Takemura N, Saiura A, Koga R, Arita J, Yoshioka R, Ono Y, et al. Long-term outcomes after surgical resection for gastric cancer liver metastasis: an analysis of 64 macroscopically complete resections. Langenbecks Arch Surg. 2012;397(6):951–7.

    Article  PubMed  Google Scholar 

  14. Chang JC. How to differentiate neoplastic fever from infectious fever in patients with cancer: usefulness of the naproxen test. Heart Lung. 1987;16(2):122–7.

    CAS  PubMed  Google Scholar 

  15. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer−pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol. 2004;22(12):2395–403.

    Article  PubMed  Google Scholar 

  16. Chau I, Ashley S, Cunningham D. Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study. J Clin Oncol. 2009;27(19):e3–4.

    Article  PubMed  Google Scholar 

  17. Hwang JE, Kim SH, Jin J, Hong JY, Kim MJ, Jung SH, et al. Combination of percutaneous radiofrequency ablation and systemic chemotherapy are effective treatment modalities for metachronous liver metastases from gastric cancer. Clin Exp Metastasis. 2014;31(1):25–32.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D’Amico TA, Das P, et al. Gastric cancer. J Natl Compr Canc Netw. 2010;8(4):378–409.

    CAS  PubMed  Google Scholar 

  19. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. [Journal Article; Practice Guideline]. 2011 2011-06-01;14(2):113–23.

  20. Kerkar SP, Kemp CD, Avital I. Liver resections in metastatic gastric cancer. HPB (Oxford). 2010;12(9):589–96.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Makino H, Kunisaki C, Izumisawa Y, Tokuhisa M, Oshima T, Nagano Y, et al. Indication for hepatic resection in the treatment of liver metastasis from gastric cancer. Anticancer Res. 2010;30(6):2367–76.

    PubMed  Google Scholar 

  22. Tiberio GA, Coniglio A, Marchet A, Marrelli D, Giacopuzzi S, Baiocchi L, et al. Metachronous hepatic metastases from gastric carcinoma: a multicentric survey. Eur J Surg Oncol. 2009;35(5):486–91.

    Article  CAS  PubMed  Google Scholar 

  23. Ueda K, Iwahashi M, Nakamori M, Nakamura M, Naka T, Ishida K, et al. Analysis of the prognostic factors and evaluation of surgical treatment for synchronous liver metastases from gastric cancer. Langenbecks Arch Surg. 2009;394(4):647–53.

    Article  PubMed  Google Scholar 

  24. Adam R, Chiche L, Aloia T, Elias D, Salmon R, Rivoire M, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg. 2006;244(4):524–35.

    PubMed Central  PubMed  Google Scholar 

  25. Kodera Y, Fujitani K, Fukushima N, Ito S, Muro K, Ohashi N, et al. Surgical resection of hepatic metastasis from gastric cancer: a review and new recommendation in the Japanese gastric cancer treatment guidelines. Gastric Cancer. 2014;17(2):206–12.

    Article  PubMed  Google Scholar 

  26. Nomura T, Kamio Y, Takasu N, Moriya T, Takeshita A, Mizutani M, et al. Intrahepatic micrometastases around liver metastases from gastric cancer. J Hepatobiliary Pancreat Surg. 2009;16(4):493–501.

    Article  PubMed  Google Scholar 

  27. Komeda K, Hayashi M, Kubo S, Nagano H, Nakai T, Kaibori M, et al. High Survival in Patients Operated for Small Isolated Liver Metastases from Gastric Cancer: A Multi-institutional Study. World J Surg. 2014 .

  28. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36–46.

    Article  CAS  PubMed  Google Scholar 

  29. Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, et al. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol. 2014;140(2):319–28.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012;30(13):1513–8.

    Article  CAS  PubMed  Google Scholar 

  31. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.

    Article  CAS  PubMed  Google Scholar 

  32. Yokoyama H, Ikehara Y, Kodera Y, Ikehara S, Yatabe Y, Mochizuki Y, et al. Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. Br J Cancer. 2006;95(11):1504–13.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 2013;31(26):3219–25.

    Article  CAS  PubMed  Google Scholar 

  34. Wang YN, Shen KT, Ling JQ, Gao XD, Hou YY, Wang XF, et al. Prognostic analysis of combined curative resection of the stomach and liver lesions in 30 gastric cancer patients with synchronous liver metastases. BMC Surg. 2012;12:20.

    Article  PubMed Central  PubMed  Google Scholar 

  35. Ambiru S, Miyazaki M, Ito H, Nakagawa K, Shimizu H, Yoshidome H, et al. Benefits and limits of hepatic resection for gastric metastases. Am J Surg. 2001;181(3):279–83.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (no: 81273187).

Conflict of interest

The authors declare that they have no conflicts of interests.

Author information

Author notes

    Authors and Affiliations

    1. Department of Oncology, Zhongshan Hospital of Fudan University, Shanghai, 200032, China

      W. Zhang, Y. Yu, Y. Wang, Y. Cui & T. Liu

    2. Department of General Surgery, Zhongshan Hospital of Fudan University, Shanghai, 200032, China

      Y. Fang & K. Shen

    Authors
    1. W. Zhang
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Y. Yu
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Y. Fang
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Y. Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Y. Cui
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. K. Shen
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. T. Liu
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to T. Liu.

    Additional information

    W. Zhang and Y. Yu contributed equally to this work.

    Electronic supplementary material

    Below is the link to the electronic supplementary material.

    Supplementary material 1 (DOCX 14 kb)

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Zhang, W., Yu, Y., Fang, Y. et al. Systemic chemotherapy as a main strategy for liver metastases from gastric cancer. Clin Transl Oncol 17, 888–894 (2015). https://doi.org/10.1007/s12094-015-1321-z

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s12094-015-1321-z

    Keywords

    Search

    Navigation